<DOC>
	<DOCNO>NCT00495066</DOCNO>
	<brief_summary>The primary objective study provide treatment Ipilimumab subject serious immediately life-threatening unresectable Stage III Stage IV melanoma , alternative treatment option , whose physician believe , base upon available data benefit risk , appropriate administer Ipilimumab dose 3 mg/kg induction ( re-induction , eligible ) , eligible subject previously enrol Ipilimumab study CA184-042 , CA184-078 , CA184-087 , MDX010-16 , MDX010-20 .</brief_summary>
	<brief_title>Compassionate Use Trial Unresectable Melanoma With Ipilimumab</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed Written Informed Consent Histologically confirm Stage III ( unresectable ) Stage IV melanoma Must fail least one systemic therapy malignant melanoma intolerant least one prior systemic treatment . Note : Enrollees must eligible clinical study Ipilimumab Subjects asymptomatic brain metastasis eligible Primary ocular mucosal melanoma allow Must least 28 day since treatment chemotherapy , biochemotherapy , immunotherapy , recover clinically significant toxicity experience treatment . Must recover prior surgery radiation . Systemic corticosteroid eliminate weaned minimum dose start Ipilimumab treatment . Consult Medical Monitor individual subject Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 2 Life expectancy ≥ 16 week Subjects must complete set baseline ( screening/baseline ) radiographic image , include limited brain , chest , abdomen , pelvis . Bone scan complete clinically indicate . The image accept obtained 6 week initiation Ipilimumab Required value initial laboratory test : 1 . White Blood Cells ( WBC ) : ≥ 2000/uL ( ≥ 2 x 10*9*/L ) 2 . Antigen Neutrophil Count ( ANC ) : ≥ 1000/uL ( ≥ 1 x 10*9*/L ) 3 . Platelets : ≥ 75 x 103/uL ( ≥ 75 x 10*9*/L ) 4 . Hemoglobin : ≥ 9 g/dL ( ≥ 80 g/L ; may transfuse ) 5 . Creatinine : ≤ 2.0 x ULN Aspartate Aminotransferase ( AST ) /Alanine Aminotransferase ( ALT ) : ≤ 2.5 x Upper Limit Normal ( ULN ) subject without liver metastasis ≤ 5 time liver metastasis Bilirubin : ≤ 2.0 x ULN ( except subject Gilbert 's Syndrome , must total bilirubin less 3.0 mg/dL ) Men woman , least 16 year age Prior treatment antiCytotoxic Tlymphocyte Associated Protein 4 ( CTLA4 ) drug allow provide therapy discontinue drugrelated toxicity Women childbearing potential ( WOCBP ) partner must use highly effective method birth control ( double barrier , e.g , condom diaphragm cervical cap associate spermicide intrauterine device combine another form birth control ) 12 week last dose study drug minimize risk pregnancy WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) Screening within 24 hour prior start investigational product Women childbearing potential ( i.e. , postmenopausal surgically sterile Men father potential must use adequate method contraception avoid conception throughout study 12 week last dose investigational product manner risk pregnancy minimize Women ChildBearing Potential ( WOCBP ) unwilling unable use acceptable method avoid pregnancy entire study 12 week last dose investigational product WOCBP use prohibit contraceptive method Women pregnant breastfeed Women positive pregnancy test enrollment investigational product administration Subjects systemic therapy cancer , include experimental treatment Prior treatment anti CTLA 4 antibody treatment failure due ImmuneRelated Adverse Events ( irAEs ) discontinuation due Adverse Event ( AE ) /Serious Adverse Event ( SAE ) Any subject enrol registrational study ( ie , CA184024 ) survival endpoint enrol CA184045 . Also , subject eligible treatment study , eligible study Presence active autoimmune disease Presence know hepatitis B hepatitis C ( active ) infection , regardless control antiviral therapy Any subject life threaten condition require highdose immunosuppressant Subjects melanoma another active , concurrent , malignant disease , exception adequately treat basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix Any nononcology vaccine therapy use prevention infectious diseases 4 week dose Ipilimumab , exception Amantadine Flumadine Any subject enrol registrational study ( ie , CA184024 ) survival primary endpoint enrol CA184045 . Also , subject eligible treatment study , eligible study Subjects study CA184042 , CA184078 CA184087 , follow survival scan eligible study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>